Context Several recent phase 2 and 3 trials have evaluated the efficacy and toxicity of
checkpoint inhibitor (CPI) therapy for urothelial carcinoma (UC) in the metastatic, localized …

Simple Summary The clinical management of bladder cancer has been developing in the
past decade, including diagnostic tools and treatment options. Both monotherapy and …

Abstract Purpose: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-
checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle …

PURPOSE The integration of immunotherapy in the perioperative setting of muscle-invasive
urothelial carcinoma (MIUC) appears promising. SAKK 06/17 investigated the addition of …

A comprehensive search regarding programmed cell death protein 1 (PD‑1)/programmed
death‑ligand 1 (PD‑L1) inhibitor monotherapy or combination therapy in neoadjuvant …

Opinion Statement There is an acute unmet need to develop novel treatment regimens in the
perioperative setting since many patients with muscle-invasive bladder cancer (MIBC) are …

Background Platinum-based neoadjuvant chemotherapy (NAC) is standard for patients with
muscle-invasive bladder cancer (MIBC). Pathologic response (complete: ypT0N0 and …

Simple Summary The risk of recurrence of patients with localized muscle-invasive bladder
carcinoma (MIBC) is still high. The outcomes of surgery and perioperative therapy are …

Introduction This meta-analysis aims to evaluate the efficacy and safety of neoadjuvant PD-1
inhibitors or PD-L1 inhibitors [PD-(L) 1 inhibitors] for muscle-invasive bladder carcinoma …

UPP1, a crucial pyrimidine metabolism-related enzyme, catalyzes the reversible
phosphorylation of uridine to uracil and ribose-1-phosphate. However, the effects of UPP1 in …